Entrada starts Phase 1 for Duchenne

 Initiated a Phase 1 clinical trial of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy, marking Entrada’s transition to a clinical-stage company –

– Expanded the Company’s Duchenne franchise with the selection of its third clinical candidate, ENTR-601-50, for the potential treatment of people living with Duchenne who are exon 50 skipping amenable –

– Cash runway expected through 2025 with $354 million in cash, cash equivalents and marketable securities as of September 30, 2023 –

https://www.globenewswire.com/news-release/2023/11/07/2774935/0/en/Entrada-Therapeutics-Reports-Third-Quarter-2023-Financial-Results.html